JUV-161 was discovered using Juvena’s proprietary JuvNET platform, an AI and stem cell secretome-based drug discovery and development platform “JUV-161 is a natural, endocrine protein therapy that ...

Many drugs work by targeting proteins. Biologic medicines showed that proteins can be made into therapies too—in some cases using proteins from the body. Juvena Therapeutics works with a type of ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announced ...

PALO ALTO, Calif., Feb. 2, 2022 /PRNewswire/ -- Juvena Therapeutics, a biopharma company whose computationally driven platform discovers and develops stem cell derived protein therapeutics for chronic ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Juvena Therapeutics, a biotechnology company unlocking the potential of stem cell-secreted proteins to treat muscle and metabolic diseases including muscular ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a partnership with Juvena Therapeutics to develop new muscle-boosting drugs. The ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and more than $650 million in milestones. The partners will use Juvena’s ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Juvena Therapeutics CEO Hanadie ...

Biotechnology startup Juvena Therapeutics Inc. has raised $41 million in new venture-capital funding to advance technology that could expand the range of treatments for chronic conditions and diseases ...

Co-led by Mubadala Capital and Horizons Ventures, funding will power Juvena’s artificial intelligence-enabled drug discovery platform to map the therapeutic potential of secreted proteins REDWOOD CITY ...